Has Amir Harari, MD received payments from drug or device companies?

Yes. Drug and device makers reported $361,322 in general payments to Amir Harari, MD across 1,260 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amir Harari, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amir Harari, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amir Harari, MD

Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1578537353

Payments from drug & device makers

$361,322in general payments, 2019–2025

Across 1,260 payments — averaging $286.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$256K
Abbott$29K
Lilly USA, LLC$26K
Ascensia Diabetes Care US Inc.$20K
Johnson & Johnson$10K
Senseonics, Incorporated$8K
plus $12K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	441	$255,722
Abbott	82	$29,491
Lilly USA, LLC	174	$26,294
Ascensia Diabetes Care US Inc.	17	$19,538
Johnson & Johnson	24	$9,827
Senseonics, Incorporated	14	$8,144
Corcept Therapeutics	33	$2,578
Amgen(2 entities)	49	$825
Medtronic(2 entities)	19	$665
Radius Health, Inc.	34	$631
AstraZeneca(2 entities)	38	$620
Dexcom, Inc.	26	$561
BETA Bionics, Inc.	41	$535
Intra-sana Laboratories	1	$500
AbbVie	23	$491
Boehringer Ingelheim	27	$462
Xeris Pharmaceuticals, Inc.	17	$449
Recordati_rare_diseases_inc.	6	$406
Sanofi-aventis U.S. LLC	28	$383
Amneal Pharmaceuticals LLC	21	$272
Antares Pharma, Inc.	12	$217
Bayer	14	$216
Sequel Med Tech, LLC	4	$187
Insulet Corporation	11	$181
Astellas Pharma US Inc	4	$169
Madrigal Pharmaceuticals	6	$168
Lifescan, Inc.	5	$157
Cequr Corporation	2	$152
Merck	13	$136
Tandem Diabetes Care, Inc.	7	$115
Ascendis Pharma Endocrinology Inc	6	$114
Mannkind Corporation	6	$89
Verity Pharmaceuticals Inc.	4	$77
Novartis	3	$68
Halozyme Inc	3	$57
Neurocrine Biosciences, Inc.	2	$56
Amarin Pharma, Inc.	4	$53
Tolmar, Inc.	3	$53
Amphastar Pharmaceuticals, Inc.	3	$51
Amryt Pharma Holdings Ltd	2	$48
GE HealthCare	2	$47
Averitas Pharma Inc.	2	$43
Shire North American Group Inc	3	$40
Embecta Corp.	2	$36
IBSA Pharma Inc.	2	$34
Alnylam Pharmaceuticals Inc.	2	$33
Valeritas, Inc.	2	$32
Sandoz	1	$31
Janssen Scientific Affairs, LLC	2	$31
GSK	1	$27
Kyowa Kirin, Inc.	1	$26
Globus Medical	1	$25
Chiesi USA, Inc.	1	$24
Soleno Therapeutics, Inc.	1	$21
Vivus LLC	2	$21
Inspire Medical Systems, Inc.	1	$20
Ionis Pharmaceuticals, Inc.	1	$17
Companion Medical, Inc.	1	$16
Rhythm Pharmaceuticals, Inc.	1	$15
Clarus Therapeutics Inc.	1	$14

How this compares

$361,322 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona →

Medicare billing

Part B allowed, 2024

$557,027

Medicare patients

1,357

Services billed

17,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Scottsdale

Kristina BlohmScottsdale$220K
Andrea FerencziScottsdale$137K
Abdul Razzak AlamirScottsdale$34K
Sreedevi ReddyScottsdale$28K
Grace Zlaket MattaScottsdale$17K
Heather SaranScottsdale$14K
Chandana MishraScottsdale$11K
Vincent LiouScottsdale$10K
Kimberlee BrontsemaScottsdale$9K
Dena HaddadScottsdale$8K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →